What a difference five years can make. Just look at Eli Lilly (LLY 14.56%). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer, and Merck boasting larger market caps. Today, Lilly ranks …
Eli Lilly’s stock surged 16% after the company announced Phase 3 trial results for its oral weight-loss drug, Orforglipron, positioning it as a potential competitor to injectable treatments. Meanwhile, rival Novo Nordisk’s shares dropped sharply. …
Dr. Rekha Kumar, endocrinologist and obesity medicine expert at Weill Cornell Medicine, joined ABC News Live to discuss the promising results from Eli Lilly's newly announced weight loss pill. April 17, 2025
April 17 (UPI) -- People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker announced Thursday. "We are pleased to see that …
Eli Lilly’s experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year. Shares jumped 16 percent as …
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company compared to those of its Danish rival. In pronouncing the …
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said …
REUTERS/BRENDAN MCDERMID/FILE PHOTO Traders work on the floor at the New York Stock Exchange in New York City, on Tuesday. Wall Street stocks ended mixed today, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations …
Eli Lilly has shared positive Phase III clinical trial data of its investigational, oral glucagon-like peptide-1 (GLP-1), orforglipron in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. In the ACHIEVE-1 study …
&
